GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Experimental Hematology, Elsevier BV, Vol. 100 ( 2021-08), p. S85-
    Type of Medium: Online Resource
    ISSN: 0301-472X
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2021
    detail.hit.zdb_id: 2005403-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Blood, American Society of Hematology, Vol. 136, No. Supplement 1 ( 2020-11-5), p. 3-3
    Abstract: Somatic mutations in catalytic arginine residues of isocitrate dehydrogenases IDH1 and IDH2 occur frequently in myeloid malignancies. Heterozygous mutation of cytosolic IDH1 or mitochondrial IDH2 contributes to leukemia development by accumulating the oncometabolite (R)-2-hydroxyglutarate (R-2-HG), causing alterations of histone and DNA methylation through impaired α-ketoglutarate-dependent dioxygenases. Small molecule inhibitors ivosidenib and enasidenib, which specifically target mutant IDH1 and IDH2 respectively, are now approved for the treatment of newly diagnosed and/or relapsed/refractory acute myeloid leukemia (AML) patients with IDH1/2 mutations. However, multiple cases of therapeutic resistance to IDH inhibitors were reported. Distinct mechanisms were described for clinical resistance of IDH inhibition, such as the acquisition of secondary mutations in cis or trans on the allosteric binding site of IDH inhibitors or isoform switching. Although a few amino acid substitutions including IDH1-S280F, IDH2-Q316E and IDH2-I319M were identified to be associated with acquired resistance, the extent to which the mutational repertoire at IDH1/2 proteins and the associated mechanisms contribute to acquired resistance to IDH inhibition remains unknown. In this study, we systematically examined all potential amino acid substitution mutations on IDH1 and IDH2 by multiple orthogonal saturating mutagenesis screens in base-edited myeloid leukemia cells. We first engineered independent myeloid leukemia cell lines containing endogenous patient-derived IDH1/2 mutations by CRISPR/Cas9-mediated base-editing. We created clonal leukemia cell lines containing heterozygous IDH1-R132H (IDH1R132H/WT) or IDH2-R140Q (IDH2R140Q/WT) mutations, which are the most frequent IDH1/2 mutations in AML. The base-edited IDH1 or IDH2-mutant leukemia cells were characterized by the accumulation of the oncometabolite R-2-HG, alterations of histone and DNA methylation, and aberrant cytokine-independent cell growth. To identify all possible amino acid substitution mutations with resistance to IDH inhibition, we performed MITE-seq-based saturation variant screens, in which each amino acid was systematically substituted by all other possible amino acids, in base-edited leukemia cells. We not only validated known mutations such as IDH1-S280F, IDH2-Q316E and IDH2-I319M, but also identified a list of de novo amino acid substitutions associated with acquired resistance to IDH inhibition. Furthermore, the base-edited leukemia cells were treated continuously with ivosidenib and enasidenib up to 16 weeks to identify acquired resistance-associated IDH1/2 mutations by next-generation sequencing. Finally, we performed ultra-deep targeted sequencing of IDH1/2 genes in 11 paired diagnosis and relapsed AML samples in patients treated with ivosidenib or enasidenib as monotherapy, and identified significantly enriched IDH1/2 secondary mutations in the relapsed samples as compared to AML samples at diagnosis. Integrative analyses of multiple orthogonal mutagenesis screens uncovered a compendium of high-confidence and clinically relevant IDH1/2 mutations with resistance to IDH inhibition. Structural modelling of IDH1/2 mutation-associated protein domains provided new insights into the mechanisms for acquired resistance due to dysregulated protein 3D structure, co-factor binding, and/or steric hindrance with the binding of small molecular inhibitors. Follow-up functional studies established new IDH mutations as candidate drivers of acquired resistance to IDH inhibition through distinct mechanisms in AML. Taken together, we generated isogenic, base-edited IDH1/2 mutant myeloid leukemia cells and identified candidate amino acid substitutions conferring resistance to IDH inhibition through orthogonal saturating variant screens. We integrated the results with targeted sequencing of IDH1/2 mutations in AML patients, structural modeling, and functional studies. Our findings not only uncover de novo pathogenic mutations associated with resistance to IDH inhibition, but also provide new insights into the molecular mechanisms for acquired resistance to a targeted therapy in AML. Disclosures No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2020
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    In: Experimental Hematology, Elsevier BV, Vol. 111 ( 2022), p. S124-S125
    Type of Medium: Online Resource
    ISSN: 0301-472X
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2022
    detail.hit.zdb_id: 2005403-8
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Cell, Elsevier BV, Vol. 170, No. 5 ( 2017-08), p. 1028-1043.e19
    Type of Medium: Online Resource
    ISSN: 0092-8674
    RVK:
    RVK:
    Language: English
    Publisher: Elsevier BV
    Publication Date: 2017
    detail.hit.zdb_id: 187009-9
    detail.hit.zdb_id: 2001951-8
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Blood, American Society of Hematology, Vol. 128, No. 22 ( 2016-12-02), p. 1038-1038
    Abstract: The developing hematopoietic system requires an exquisite coordination of gene expression and metabolism. Mitochondria are critical for heme and iron metabolism in erythroid cells, yet their regulation during normal erythropoiesis remains largely unknown. Previously we determined the genome-scale protein and mRNA expression in human primary CD34+ hematopoietic stem/progenitor cells (HSPCs) and erythroid precursors (proerythroblasts or ProEs) by mass-spectrometry-based quantitative proteomics and RNA-seq analysis, respectively. In-depth proteomic profiling resulted in identification and quantification of proteins encoded by 14,502 genes, 13,341 of which are assigned to their corresponding transcripts detected by RNA-seq. Through unbiased comparison of the proteomic and transcriptomic changes between HSPCs and ProEs, we unexpectedly uncovered major pathways related to mitochondrial biogenesis enhanced through post-transcriptional mechanisms. Mitochondrial activities, as measured by mitochondrial mass, membrane potential and intracellular ATP, and associated metabolites are dynamically regulated during erythroid development. Expression of mitochondrial factors including mitochondrial transcription factor A (TFAM), a key regulator of mitochondrial DNA replication and transcription, is markedly increased without changes in the cognate mRNAs during erythropoiesis. Consistently, through analysis of protein synthesis by polysome profiling in HSPCs and ProEs, we demonstrated that mitochondria-associated proteins are specifically increased through enhanced protein translation. To establish the in vivo role of mitochondria in normal erythroid development, we generated Tfam conditional knockout (KO) mice by an erythroid-specific EpoR-Cre allele. Tfam KO embryos are anemic and display defective erythroid differentiation of CD71+Ter119- progenitor cells to lineage-committed CD71+Ter119+ erythroid cells. By RNA-seq analysis of Tfam WT and KO E13.5 fetal liver Ter119+CD71+ cells, we found that Tfam KO erythroid cells are severely impaired in mitochondrial biogenesis and metabolism. Specifically, mitochondrial signature genes and genes associated with reactive oxygen species pathway, TCA cycle and heme metabolism are significantly downregulated, whereas HSPC-specific genes are markedly upregulated in Tfam KO erythroid cells. Changes in intracellular metabolism often results in altered epigenetic gene regulation. We then measured the levels of histone modifications in Tfam KO erythroid cells. Strikingly, the levels of acetylated histones including H3K9ac and H3K27ac are markedly increased, whereas the levels of methylated or unmodified histones remain largely unchanged, indicating that Tfam loss leads to a hyperacetylated chromatin. By ChIP-seq analysis of H3K27ac in Tfam WT vs KO erythroid cells, we found that histone acetylation is significantly increased at HSPC-specific genes, consistent with the derepression of HSPC genes in Tfam-deficient erythroid cells. To establish the causality, we found by metabolomic profiling that Tfam-deficient erythroid cells display defective intracellular metabolism affecting several major metabolic pathways. Most importantly, the metabolic intermediate β-hydroxybutyrate (βOHB), a ketone body synthesized from acetyl-CoA, is significantly upregulated and functions as a potent HDAC inhibitor, resulting in histone hyperacetylation in Tfam-deficient erythroid cells. Treatment of human HSPCs with βOHB significantly impairs erythroid differentiation and gene expression, similar to the phenotypes observed in Tfam KO erythroid cells. Collectively, our studies support a mechanism for proper regulation of mitochondrial biogenesis by post-transcriptional machinery, and establish a new molecular link between mitochondrial biogenesis, metabolism and epigenetic gene regulation indispensable for normal erythropoiesis. Mitochondrial dysfunction leads to a variety of human disorders with impaired erythropoiesis being a severe manifestation in a subset of these diseases. Therefore, our findings provide a mechanistic explanation for the broad notion that red blood cells are uniquely sensitive to perturbations that affect protein translation and/or mitochondrial activities, and may have direct relevance to the hematological defects associated with mitochondrial diseases and aging. Disclosures DeBerardinis: Agios Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Peloton Therapeutics: Membership on an entity's Board of Directors or advisory committees.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2016
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    In: Nature Genetics, Springer Science and Business Media LLC, Vol. 53, No. 5 ( 2021-05), p. 672-682
    Type of Medium: Online Resource
    ISSN: 1061-4036 , 1546-1718
    RVK:
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2021
    detail.hit.zdb_id: 1494946-5
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...